Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Arcutis Biotherapeutics, Inc.

NASDAQ: ARQT · Life Sciences · 8 alerts · CIK 1787306

Share price
$27.15Close, Nov 16
Market cap
$3.43B
Shares outstanding
126.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Arcutis Biotherapeutics, Inc. filings on SEC EDGAR ↗

4:05 PM ET 10-Q
Financial Results

Arcutis Biotherapeutics Q3 2026 Results: Net Income $8.8M, Up 18.8% YoY

Arcutis Biotherapeutics reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $12.5 million compared to a net loss of $33.5 million in the prior year period. This growth was driven by a 55% increase in net product revenue to $379.2 million, though operating expenses also rose to $362.4 million due to higher selling, general, and administrative costs.

Key figure
Net income $8.8M · +18.8% YoY
4:03 PM ET 8-K
Financial Results

Arcutis Biotherapeutics Financial Results

Arcutis Biotherapeutics reported Q3 2026 net product revenues of $143.9 million, a 45% year-over-year increase driven by strong demand for its ZORYVE portfolio. The company maintained positive operating cash flow of $18.9 million and raised its full-year 2026 net product sales guidance to a range of $535 million to $545 million.

Term
quarter ended September 30, 2026

“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations.”

Frank Watanabe, president and chief executive officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.